We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+12.8%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$3.21B
AUM Growth
-$296M
Cap. Flow
-$592M
Cap. Flow %
-18.42%
Top 10 Hldgs %
43.24%
Holding
304
New
89
Increased
36
Reduced
82
Closed
88

Top Buys

Rank Stock Value
1
ATAI icon
AtaiBeckley Inc
ATAI
+$25.3M
2
AGL icon
Agilon Health
AGL
+$13.5M
3
LLY icon
Eli Lilly
LLY
+$13.2M
4
PRVA icon
Privia Health
PRVA
+$12.8M
5
LNTH icon
Lantheus
LNTH
+$12.3M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$23.9M
2
VCEL icon
Vericel Corp
VCEL
+$20.8M
3
ALGN icon
Align Technology
ALGN
+$19M
4
SIBN icon
SI-BONE Inc
SIBN
+$17.5M
5
STAA icon
STAAR Surgical
STAA
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 34.64%
2 Industrials 1.41%
3 Materials 0.54%
4 Financials 0.48%
5 Consumer Staples 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOGC
176
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$1.11M 0.03%
249,256
-3,846
-2% -$19.6K
OBIO icon
177
Orchestra BioMed
OBIO
$264M
$1.1M 0.03%
107,918
-1,574
-1% -$16.3K
KDNY
178
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.04M 0.03%
+73,977
New +$1.18M
MTACU
179
DELISTED
MedTech Acquisition Corporation Unit
MTACU
$1.04M 0.03%
103,944
-186,103
-64% -$1.88M
FNCH
180
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$1.01M 0.03%
2,385
-2,948
-55% -$1.28M
ALT icon
181
CALL
Altimmune
ALT
$583M
$960K 0.03%
97,500
-2,500
-3% -$34.2K
HCAQ
182
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
$958K 0.03%
97,217
-1,010
-1% -$9.99K
EXEL icon
183
Exelixis
EXEL
$12.7B
$943K 0.03%
51,779
-14,681
-22% -$342K
BGMS
184
Bio Green Med Solution Inc
BGMS
$4.97M
$931K 0.03%
44
-32
-42% -$793K
KRYS icon
185
PUT
Krystal Biotech
KRYS
$9.68B
$850K 0.03%
+12,500
New +$872K
GOSS icon
186
Gossamer Bio
GOSS
$88.9M
$801K 0.02%
98,633
-1,621
-2% -$14.1K
ACHL
187
DELISTED
Achilles Therapeutics
ACHL
$794K 0.02%
81,126
-21,900
-21% -$297K
KA
188
DELISTED
Kineta, Inc. Common Stock
KA
$794K 0.02%
9,742
-94
-1% -$10.2K
SPKBU
189
DELISTED
Silver Spike Acquisition Corp II Units
SPKBU
$783K 0.02%
77,505
-397,495
-84% -$3.99M
XGN icon
190
Exagen
XGN
$164M
$772K 0.02%
51,502
-279,639
-84% -$4.29M
TSHA icon
191
Taysha Gene Therapies
TSHA
$2.14B
$717K 0.02%
+33,822
New +$780K
MCRB icon
192
Seres Therapeutics
MCRB
$46.6M
$716K 0.02%
+1,500
New +$633K
TBPH icon
193
Theravance Biopharma
TBPH
$878M
$708K 0.02%
+48,766
New +$916K
AVEO
194
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$643K 0.02%
+97,547
New +$673K
CTMX icon
195
CytomX Therapeutics
CTMX
$752M
$638K 0.02%
100,841
-101,637
-50% -$791K
MREO
196
Mereo BioPharma
MREO
$48.8M
$623K 0.02%
196,570
+96,056
+96% +$322K
TALKW
197
DELISTED
Talkspace Inc Warrant
TALKW
$602K 0.02%
447,556
-7,162
-2% -$9.56K
CLVS
198
DELISTED
Clovis Oncology, Inc.
CLVS
$566K 0.02%
+97,641
New +$572K
LGVN
199
Longeveron
LGVN
$21.9M
$546K 0.02%
+6,712
New +$438K
TARS icon
200
Tarsus Pharmaceuticals
TARS
$3.05B
$484K 0.02%
+16,686
New +$521K
6 7
8
9 10

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q2 2021 Portfolio in Review

As of Q2 2021, Pura Vida Investments held 304 positions worth $3.21B, down 8.4% from $3.51B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Pura Vida Investments withdrew a net $592M in Q2 2021, closing 88 positions and reducing 82 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $23.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Industrials and Materials.

Against the trend, Pura Vida Investments opened a new position in AtaiBeckley Inc worth $23.2M.

  • Pura Vida Investments's largest Q2 2021 buy was AtaiBeckley Inc: 1,371,824 shares worth $23.2M.
  • Pura Vida Investments added most to Quotient Limited Ordinary Shares in Q2 2021, an estimated $9.15M increase.
  • Pura Vida Investments's biggest Q2 2021 reduction was STAAR Surgical, cutting an estimated $14.6M.
  • Pura Vida Investments fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $23.9M.
  • Pura Vida Investments's ten largest holdings make up 43% of its $3.21B portfolio in Q2 2021.
  • Pura Vida Investments opened 89 new positions and closed 88 in Q2 2021.
  • Pura Vida Investments's portfolio value fell 8.4% quarter-over-quarter to $3.21B.

Based on Pura Vida Investments's 13F filing for Q2 2021, filed 16 Aug 2021.